Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

Cited by (759)

Items 201–300 of 759

1. Interleukin-6 Receptor Blockade Selectively Reduces IL-21 Production by CD4 T Cells and IgG4 Autoantibodies in Rheumatoid Arthritis
   G. Carbone, A. Wilson, S. Diehl, J. Bunn, S. M. Cooper, M. Rincón · 2013 · International Journal on Biological Sciences
2. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
   W. Rigby, H. Tony, K. Oelke, B. Combe, A. Laster, C. V. von Mühlen, E. Fisheleva, Carmen Martín, Helen Travers, W. Dummer · 2012 · Arthritis & Rheumatism
3. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT
   K. Gerhold, A. Richter, Matthias Schneider, H. Bergerhausen, W. Demary, A. Liebhaber, J. Listing, A. Zink, A. Strangfeld · 2015 · Rheumatology
4. Reporting of long-term extension studies: lack of consistency calls for consensus
   M. Buch, D. Aletaha, P. Emery, J. Smolen · 2011 · Annals of the Rheumatic Diseases
5. Anticytokine Therapy for Osteoarthritis
   C. Malemud · 2010 · Drugs & Aging
6. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
   M. Schoels, F. Alasti, J. Smolen, D. Aletaha · 2017 · Arthritis Research & Therapy
7. Immunomodulator therapy: Monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins
   Sang Hyuck Lee, Javier Chinen, Arthur Kavanaugh · 2009 · Journal of Allergy and Clinical Immunology
8. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
   R. Sakai, Soo-Kyung Cho, T. Nanki, Kaori Watanabe, H. Yamazaki, Michinobu Tanaka, R. Koike, Yoshiya Tanaka, Kazuyoshi Saito, S. Hirata et al. · 2015 · Arthritis Research & Therapy
9. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
   Jasvinder A. Singh, Alomgir Hossain, Elizabeth Tanjong-Ghogomu, A. Mudano, Lara J. Maxwell, R. Buchbinder, M. Lopez-Olivo, M. Suarez-Almazor, P. Tugwell, G. Wells · 2017 · Cochrane Database of Systematic Reviews
10. Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium
    J. Ducreux, P. Durez, C. Galant, A. Nzeusseu-Toukap, B. Van den Eynde, F. Houssiau, B. Lauwerys · 2014 · Arthritis & Rheumatology
11. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study
    S. Momohara, J. Hashimoto, H. Tsuboi, H. Miyahara, N. Nakagawa, A. Kaneko, N. Kondo, H. Matsuno, Takahiko Wada, T. Nonaka et al. · 2013 · Modern Rheumatology
12. Phagocytosis of Apoptotic Cells Modulates Mesenchymal Stem Cells Osteogenic Differentiation to Enhance IL-17 and RANKL Expression on CD4+ T Cells
    Gloria Hoi Wan Tso, Hkw Law, Wenwei Tu, Gcf Chan, YL Lau · 2010 · Stem Cells
13. New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression
    Scott Michael Steward-Tharp, Yun-Jeong Song, Richard M. Siegel, John J. O’Shea · 2010 · Annals of the New York Academy of Sciences
14. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
    E. Nasonov, S. Fatenejad, E. Feist, M. Ivanova, E. Korneva, D. Krechikova, A. L. Maslyanskiy, M. Samsonov, R. Stoilov, E. Zonova et al. · 2021 · Annals of the Rheumatic Diseases
15. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.
    H. Forsblad-d'Elia, K. Bengtsson, L. Kristensen, L. Jacobsson · 2015 · Rheumatology
16. Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis
    R. Launois, B. Avouac, F. Berenbaum, O. Blin, I. Bru, B. Fautrel, J. Joubert, J. Sibilia, B. Combe · 2011 · Journal of Rheumatology
17. Anti-inflammatory effects and pharmacokinetics study of geniposide on rats with adjuvant arthritis.
    Jin-Yun Chen, Hong Wu, Hui Li, Shun-Li Hu, Miao-miao Dai, Jian Chen · 2015 · International Immunopharmacology
18. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists.
    J. Jazayeri, G. Carroll, A. Vernallis · 2010 · International Immunopharmacology
19. Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?
    Francesco Buonfiglio, Elsa Wilma Böhm, Norbert Pfeiffer, Adrian Gericke · 2023 · Antioxidants
20. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis
    Mahdi Mahmoudi, Saeed Aslani, Reza Fadaei, Ahmadreza Jamshidi · 2017 · International Journal of Rheumatic Diseases
21. Tocilizumab: therapy and safety management.
    T. Pham, P. Claudepierre, A. Constantin, M. de Bandt, B. Fautrel, L. Gossec, J. Gottenberg, P. Goupille, S. Guillaume, É. Hachulla et al. · 2010 · Joint, bone, spine : revue du rhumatisme
22. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries
    Gablu Kilcher, Noemi Hummel, Eva‐Maria Didden, Matthias Egger, Stephan Reichenbach, for the GetReal Work Package 4 · 2017 · Rheumatology
23. Critical role of IL-6 in dendritic cell-induced allergic inflammation of asthma
    Yen-Lin Lin, Shun-Hua Chen, Jiu-Yao Wang · 2015 · Journal of molecular medicine
24. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
    T. Takeuchi, Yoshiya Tanaka, H. Yamanaka, K. Amano, R. Nagamine, W. Park, K. Shiozawa, M. Tsukano, J. Wei, Jing Shao et al. · 2016 · Modern Rheumatology
25. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
    Eva Salgado, José Ramón Maneiro, Loreto Carmona, Juan Jesús Gómez-Reino · 2013 · Annals of the Rheumatic Diseases
26. Tocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label, clinical practice study
    M. Weinblatt, J. Kremer, J. Cush, W. Rigby, Li-Chen L. Teng, J. Devenport, Natasha Singh, D. Lepley, M. Genovese · 2013 · Arthritis care & research
27. Advances in the treatment of rheumatoid arthritis
    N. Vivar, R. van Vollenhoven · 2014 · F1000Prime Reports
28. Infectious complications of biologic agents.
    E. Martı́n-Mola, A. Balsa · 2009 · Rheumatic Disease Clinics of North America
29. Impact of obesity on autoimmune arthritis and its cardiovascular complications
    Katrien Van Raemdonck, Sadiq Umar, Zoltán Szekanecz, Ryan K. Zomorrodi, Shiva Shahrara · 2018 · Autoimmunity Reviews
30. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
    P. Taylor, J. Kremer, P. Emery, S. Zuckerman, G. Ruotolo, J. Zhong, Lei Chen, S. Witt, C. Saifan, M. Kurzawa et al. · 2018 · Annals of the Rheumatic Diseases
31. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
    J. Morel, A. Constantin, G. Baron, E. Dernis, R. Flipo, S. Rist, B. Combe, J. Gottenberg, T. Schaeverbeke, M. Soubrier et al. · 2017 · Rheumatology
32. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials
    Priyanka Vashisht, H. Sayles, Amy C. Cannella, T. Mikuls, K. Michaud · 2016 · Arthritis care & research
33. Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.
    A. Deroux, C. Chiquet, L. Bouillet · 2016 · Seminars in Arthritis & Rheumatism
34. Fatigue in rheumatic disease: an overview
    S. Stebbings, G. Treharne · 2010 · International Journal of Clinical Rheumatology
35. Update on tocilizumab in rheumatoid arthritis: a narrative review
    S. Parisi, M. Ditto, Francesco Ghellere, S. Panaro, Francesca Piccione, R. Borrelli, E. Fusaro · 2025 · Frontiers in Immunology
36. The IL-12 cytokine family in cardiovascular diseases
    Thomas van der Heijden, Ilze Bot, Johan Kuiper · 2017 · Cytokine
37. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
    A. Rubbert-Roth, A. Sebba, Laura Brockwell, A. Kelman, Benjamin Porter-Brown, J. Pulley, P. Napalkov, R. van Vollenhoven · 2016 · RMD Open
38. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
    J. Kremer, M. Genovese, E. Keystone, P. Taylor, Steven H. Zuckerman, G. Ruotolo, D. Schlichting, Victoria L. Crotzer, E. Nantz, S. Beattie et al. · 2017 · Arthritis & Rheumatology
39. Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
    Jianmei Wang, J. Devenport, J. Low, Da-Le Yu, E. Hitraya · 2016 · Arthritis care & research
40. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis
    J. Wang, A. Bansal, Mitchell Martin, S. Germer, R. Benayed, L. Essioux, J. S. Lee, A. Begovich, A. Hemmings, A. Kenwright et al. · 2012 · The Pharmacogenomics Journal
41. Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions
    A. Ogata, Toshio Tanaka · 2012 · International Journal of Rheumatology
42. Influenza A Virus Infection Induces Muscle Wasting via IL-6 Regulation of the E3 Ubiquitin Ligase Atrogin-1
    K. Radigan, T. Nicholson, L. Welch, Monica Chi, Luciano Amarelle, Martín Angulo, M. Shigemura, Atsuko Shigemura, Constance E. Runyan, Luisa Morales-Nebreda et al. · 2018 · Journal of Immunology
43. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants
    José Inciarte-Mundo, Virginia Ruíz-Esquide, Maria Victoria Hernández, Juan de Dios Cañete, Sonia Raquel Cabrera‐Villalba, Julio Ramírez, Jordi Yagüe, Raimón Sanmartí · 2015 · Rheumatology
44. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.
    J. Curtis, S. Perez-Gutthann, S. Suissa, P. Napalkov, Natasha Singh, L. Thompson, Benjamin Porter-Brown · 2015 · Seminars in Arthritis & Rheumatism
45. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy
    A. Kaneko · 2013 · Therapeutic Advances in Chronic Disease
46. Cardiovascular safety of biologic therapies for the treatment of RA
    J. Greenberg, V. Furer, M. Farkouh · 2012 · Nature Reviews Rheumatology
47. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
    X. Teitsma, A. Marijnissen, J. Bijlsma, F. Lafeber, J. Jacobs · 2016 · Arthritis Research & Therapy
48. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis
    E. Soini, T. Hallinen, K. Puolakka, V. Vihervaara, M. Kauppi · 2012 · Journal of Medical Economics
49. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
    P. Guyot, P. Taylor, R. Christensen, L. Pericleous, C. Poncet, M. Lebmeier, P. Drost, G. Bergman · 2011 · Arthritis Research & Therapy
50. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis
    Xiao-Ping Zhang, R. Peck · 2011 · Expert Review of Clinical Pharmacology
51. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data
    M. Hama, T. Uehara, K. Takase, A. Ihata, Atsuhisa Ueda, M. Takeno, K. Shizukuishi, U. Tateishi, Y. Ishigatsubo · 2011 · Rheumatology International
52. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate
    Y. Nakashima, M. Kondo, H. Harada, T. Horiuchi, T. Ishinishi, H. Jôjima, K. Kuroda, H. Miyahara, R. Nagamine, H. Nakashima et al. · 2010 · Modern Rheumatology
53. Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system
    Rohitas Deshmukh · 2023 · Materials Today Communications
54. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
    P. Conaghan, C. Peterfy, E. Olech, J. Kaine, D. Ridley, J. DiCarlo, J. Friedman, J. Devenport, O. Troum · 2014 · Annals of the Rheumatic Diseases
55. Guidelines for the drug treatment of rheumatoid arthritis.
    Licia Maria Henrique da Mota, B. A. Cruz, C. Brenol, I. Pereira, L. S. Rezende-Fronza, M. Bértolo, M. V. Freitas, N. D. da Silva, P. Louzada-Júnior, R. Giorgi et al. · 2013 · Revista Brasileira de Reumatologia
56. Clinical safety of tocilizumab in rheumatoid arthritis
    B. Bannwarth, C. Richez · 2011 · Expert Opinion on Drug Safety
57. Tocilizumab
    Scheinecker, Clemens, Smolen, Josef, Yasothan, Uma, Stoll, Jeffrey, Kirkpatrick, Peter · 2009 · Nature Reviews Drug Discovery
58. Translating JAKs to Jakinibs
    M. Gadina, Danielle A Chisolm, Rachael L. Philips, Iain B. McInness, P. Changelian, J. O'Shea · 2020 · Journal of Immunology
59. Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors
    J. Bilal, Adam J. Berlinberg, I. Bin Riaz, W. Faridi, S. Bhattacharjee, G. Ortega, M. Murad, Zhen Wang, L. Prokop, Abdullah A. Alhifany et al. · 2019 · JAMA Network Open
60. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis
    Alberto Jiménez Morales, M. Maldonado-Montoro, J. E. Martínez-de la Plata, Cristina Pérez Ramírez, A. Daddaoua, Carolina Alarcón Payer, Manuela Expósito Ruíz, Carlos García Collado · 2018 · Journal of clinical pharmacology
61. Regulation Generation: The Suppressive Functions of Human Regulatory T Cells
    Wendy A. Goodman, K. Cooper, T. McCormick · 2012 · Critical Reviews in Immunology
62. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis
    E. Turkstra, S. Ng, P. Scuffham · 2011 · Current Medical Research and Opinion
63. Neutrophil Homeostasis and Emergency Granulopoiesis: The Example of Systemic Juvenile Idiopathic Arthritis
    Bert Malengier‐Devlies, Mieke Metzemaekers, Carine Helena Wouters, Paul Proost, Patrick Matthys · 2021 · Frontiers in Immunology
64. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    C. Díaz-Torné, M. A. Ortiz, P. Moya, M. V. Hernández, D. Reina, I. Castellví, J. de Agustín, D. de la Fuente, H. Corominas, R. Sanmartí et al. · 2017 · Seminars in Arthritis & Rheumatism
65. The use of unequal randomisation in clinical trials--An update.
    E. Peckham, S. Brabyn, Liz Cook, Thomas Devlin, J. Dumville, D. Torgerson · 2015 · Contemporary Clinical Trials
66. Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis
    M. Levi, S. Grange, N. Frey · 2013 · Journal of clinical pharmacology
67. Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger
    Tamotsu Kamishima, K. Tanimura, M. Shimizu, Megumi Matsuhashi, J. Fukae, Yujiro Kon, Hiromi Hagiwara, Akihiro Narita, Y. Aoki, Naoki Kosaka et al. · 2011 · Skeletal Radiology
68. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis
    R. Yip, Cheuk-Wan Yim · 2019 · Journal of clinical rheumatology
69. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab
    J. Kremer, W. Rigby, Nora G. Singer, C. Birchwood, D. Gill, W. Reiss, J. Pei, M. Michalska · 2018 · Arthritis & Rheumatology
70. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study
    A. Ogata, K. Amano, H. Dobashi, M. Inoo, T. Ishii, T. Kasama, S. Kawai, A. Kawakami, T. Koike, H. Miyahara et al. · 2015 · Journal of Rheumatology
71. Cardiovascular Disease and Rheumatoid Arthritis: An Update
    C. Charles-Schoeman · 2012 · Current Rheumatology Reports
72. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
    Cyrille B. Confavreux, Roland D Chapurlat · 2010 · Osteoporosis International
73. Tocilizumab for rheumatoid arthritis
    Jasvinder A. Singh, Saba Beg, Maria Angeles Lopez-Olivo · 2010 · Cochrane Database of Systematic Reviews
74. Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
    Steven S. Storage, Harsh Agrawal, D. Furst · 2010 · The Korean Journal of Internal Medicine
75. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy
    Soken-Nakazawa J. Song, Kazuyuki Yoshizaki · 2014 · Expert Opinion on Drug Metabolism & Toxicology
76. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach
    L. Gibiansky, N. Frey · 2012 · Journal of Pharmacokinetics and Pharmacodynamics
77. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy
    A. Diamantopoulos, M. Benucci, S. Capri, W. Berger, N. Wintfeld, G. Giuliani, W. Ricciardi · 2012 · Journal of Medical Economics
78. Immunotherapeutic Implication of IL-6 Blockade
    Toshio Tanaka, Tadamitsu Kishimoto · 2011 · Immunotherapy
79. IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives
    Michal Španko, Karolína Strnadová, Aleš Jan Pavlíček, Pavol Szabó, Ondřej Kodet, Jaroslav Valach, Barbora Dvořánková, Karel Smetana, Lukáš Lacina · 2021 · International Journal of Molecular Sciences
80. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice
    Marina Backhaus, J. Kaufmann, C. Richter, S. Wassenberg, A. Roske, P. Hellmann, M. Gaubitz · 2015 · Clinical Rheumatology
81. Recent concepts in the inhibition of radiographic progression with biologics
    E. Keystone · 2009 · Current Opinion in Rheumatology
82. Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis
    J. Molina, Raimon Sanmartí Sala, V. Valverde, E. Mola, J. L. Marenco de la Fuente, I. G. Álvaro, S. M. Fernández, J. G. Carnota, Luis Carreño Pérez, Enrique Batlle Gualda et al. · 2010 · Reumatología Clínica (English Edition)
83. Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study
    Murali Ramaswamy, P. Mannam, R. Comer, Emily Sinclair, D. B. McQuaid, Monica L. Schmidt · 2020 · medRxiv
84. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan
    Shunsuke Mori, Tamami Yoshitama, Toshihiko Hidaka, Fumikazu Sakai, Mizue Hasegawa, Yayoi Hashiba, Eiichi Suematsu, Hiroshi Tatsukawa, Akinari Mizokami, Shigeru Yoshizawa et al. · 2017 · PLoS ONE
85. New treatment options for noninfectious uveitis.
    Millena Gomes Bittencourt, Y. Sepah, D. Do, Owhofasa O. Agbedia, Abeer Akhtar, Hong-Ting Liu, A. Akhlaq, R. Annam, M. Ibrahim, Q. Nguyen · 2012 · Developments in ophthalmology
86. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
    C. Iking-Konert, U. von Hinüber, C. Richter, H. Schwenke, I. Gürtler, P. Kästner, Birgit Klapperich, M. Peters, G. Burmester · 2016 · Rheumatology
87. Glucocorticoid‐Induced Leucine Zipper Governs the Therapeutic Potential of Mesenchymal Stem Cells by Inducing a Switch From Pathogenic to Regulatory Th17 Cells in a Mouse Model of Collagen‐Induced Arthritis
    P. Luz-Crawford, G. Tejedor, Anne-Laure Mausset-Bonnefont, É. Beaulieu, E. Morand, C. Jørgensen, D. Noël, F. Djouad · 2015 · Arthritis & Rheumatology
88. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis
    Yoshihiro Hishitani, Atsushi Ogata, Y. Shima, Toshio Hirano, K. Ebina, Y. Kunugiza, K. Shi, M. Narazaki, K. Hagihara, Tetsuya Tomita et al. · 2013 · Scandinavian Journal of Rheumatology
89. 2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis
    Xin-Ping Tian, Qian Wang, Meng-Tao Li, Yan Zhao, Zhi-Yi Zhang, Ci-Bo Huang, Yi Liu, Hu-Ji Xu, Yao-Long Chen, Li-Jun Wu et al. · 2021 · Rheumatology and Immunology Research
90. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    M. Covington, Xin He, M. Scuron, Jun Yu Li, Robert J. Collins, Ashish P. Juvekar, N. Shin, M. Favata, Karen Gallagher, Sarala Sarah et al. · 2020 · European Journal of Pharmacology
91. Targeting interleukin-6 in pediatric rheumatic diseases.
    F. de Benedetti · 2009 · Current Opinion in Rheumatology
92. Randomized controlled trial design in rheumatoid arthritis: the past decade
    V. Strand, J. Sokolove · 2009 · Arthritis Research & Therapy
93. Immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    J. Sigaux, M. Hamze, C. Daien, J. Morel, R. Krzysiek, M. Pallardy, B. Maillère, X. Mariette, C. Miceli-Richard · 2017 · Joint, bone, spine : revue du rhumatisme
94. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
    Eun-Jung Park, Hyungjin Kim, S. Jung, Yoon-Kyoung Sung, H. Baek, Jisoo Lee · 2020 · The Korean Journal of Internal Medicine
95. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs
    Luca Semerano, Allan Thiolat, Émeline Minichiello, Gaëlle Clavel, Natacha Bessis, Marie‐Christophe Boissier · 2014 · Expert Opinion on Investigational Drugs
96. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis
    T. Kojima, Y. Yabe, A. Kaneko, Y. Hirano, H. Ishikawa, M. Hayashi, H. Miyake, H. Takagi, T. Kato, K. Terabe et al. · 2013 · Modern Rheumatology
97. Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo?
    T. Page, Anthony C. Brown, E. Timms, B. Foxwell, K. Ray · 2010 · Arthritis & Rheumatism
98. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases.
    Susan J. Lee, M. Ballow · 2010 · Journal of Allergy and Clinical Immunology
99. Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources
    S. Monemi, E. Berber, K. Sarsour, Jianmei Wang, K. Lampl, K. Bharucha, A. Pethoe-Schramm · 2016 · Rheumatology and Therapy
100. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate.
     A. Pierreisnard, N. Issa, T. Barnetche, C. Richez, T. Schaeverbeke · 2013 · Joint, bone, spine : revue du rhumatisme